EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A multi-composite disease activity score (NFKB1-DAS) for NFKB1 insufficiency

Katharina Thoma, Pia Hassunah, Manfred Fliegauf, Gabriele Müller, Andres Caballero Garcia de Oteyza, Pavla Mrovecova, Helene Kraus, Prerana Agarwal, Maximilian Frederik Russe, Birgit Sawitzki, Lev Petrov, Katrin Vogt und 22 weitere

Journal of Clinical Immunology · 2026

DOI: 10.1007/s10875-026-02081-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2026. Verfasst von Katharina Thoma und 33 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs- Unive…. Hauptthemen laut MEDLINE: NF-kappa B p50 Subunit. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, EU-funded PhD program IMMERGE, BMBF rare disease program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NFKB1 encodes the p105/p50 NF-κB1 transcription factor. Heterozygous mutations in NFKB1 may lead to NFKB1 insufficiency affecting multiple organ systems. This study aimed to develop an NFKB1 -Disease-Activity-Score ( NFKB1 -DAS), serving as a tool in future clinical trials. Based on published phenotypic data from 179 patients with 77 distinct NFKB1 variants, we drafted an initial score consisting of 42 parameters. This draft was subsequently analyzed in a multicenter cohort of 41 patients with 22 distinct pathogenic NFKB1 variants. Using a Leave-One-Out (LOO) analysis (cutoff differential value: 23.07), we identified the 21 most relevant parameters to construct the final NFKB1 -DAS. Calculation of the NFKB1 -DAS in 31 CTLA4 -deficient patients as a comparison cohort showed higher scores in NF K B1 -insufficient patients ( p = 0.03 (95% CI [-0.16, -0.01]) and the NFKB1 -DAS correlated with hospitalization ( p = 0.01; OR 2.07 (95% CI [1.18; 3.62]). However, given the optimism bias occurring when testing the score in the cohort it was developed with and the limited case numbers, validation of the NFKB1 -DAS in an unrelated cohort remains essential. Analysis of the NFKB1 -DAS in patients with variants of unknown significance (VUS) in NFKB1 ( n = 14) showed individual patients reaching high scores. Future studies could evaluate a possible utility of the score in assessing VUS pathogenicity. Ultimately, the proposed NFKB1 -DAS represents a first step toward monitoring disease activity and treatment response in future clinical trials in NFKB1 insufficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa B p50 SubunitHumansFemaleMutationPhenotypeGenetic Predisposition to DiseaseSeverity of Illness IndexMale

Stichwörter der Autor:innen

NFKB1NFKB1-DASDisease activityNF-κB1ScoreTreatment

Substanzen

NF-kappa B p50 SubunitNFKB1 protein, human

Autor:innen und Institutionen

  • Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs- University of Freiburg, Freiburg, Germany. Katharina.thoma@uniklinik-freibu…
  • Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany. Katharina.thoma@uniklinik-freiburg.de.
  • Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs- University of Freiburg, Freiburg, Germany.
  • Institute for Immunodeficiency (IFI), Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
  • FREEZE Biobank, Center for Biobanking, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
  • Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • EU-funded PhD program IMMERGE
  • BMBF rare disease program
  • Wilhelm Sander-Stiftung

Zitieren

APA

Thoma, K., Hassunah, P., Fliegauf, M., Müller, G., Caballero Garcia de Oteyza, A., Mrovecova, P., Kraus, H., Agarwal, P., Russe, M. F., Sawitzki, B., Petrov, L., Vogt, K., Camacho Ordonez, N., Hirsch, A., Geier, C. B., Krausz, M., Goldacker, S., Frede, N., Ehl, S., …, & Grimbacher, B. (2026). A multi-composite disease activity score (NFKB1-DAS) for NFKB1 insufficiency. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-026-02081-3

Vancouver

Thoma K, Hassunah P, Fliegauf M, Müller G, Caballero Garcia de Oteyza A, Mrovecova P, et al. A multi-composite disease activity score (NFKB1-DAS) for NFKB1 insufficiency. Journal of Clinical Immunology. 2026. doi:10.1007/s10875-026-02081-3

BibTeX
@article{Thoma2026,
  author = {Thoma, Katharina and Hassunah, Pia and Fliegauf, Manfred and Müller, Gabriele and Caballero Garcia de Oteyza, Andres and Mrovecova, Pavla and Kraus, Helene and Agarwal, Prerana and Russe, Maximilian Frederik and Sawitzki, Birgit and Petrov, Lev and Vogt, Katrin and Camacho Ordonez, Nadezhda and Hirsch, Aleksandra and Geier, Christoph B and Krausz, Máté and Goldacker, Sigune and Frede, Natalie and Ehl, Stephan and Salou, Sarah and Schulz, Ansgar and Bakhtiar, Shahrzad and Fasshauer, Maria and Hausmann, Oliver and Hüfner, Anja-Dorothee and Stanulla, Martin and Luijendijk, Anna and Atschekzei, Faranaz and Sogkas, Georgios and Salzer, Ulrich and Keller, Baerbel and Proietti, Michele and Warnatz, Klaus and Grimbacher, Bodo},
  title = {A multi-composite disease activity score (NFKB1-DAS) for NFKB1 insufficiency},
  journal = {Journal of Clinical Immunology},
  year = {2026},
  doi = {10.1007/s10875-026-02081-3}
}
Kostenlos starten →